Patient-Reported and Clinical Outcomes Among Patients With Calciphylaxis.
HBO, hyperbaric oxygen
IV, intravenous
MME, morphine milligram equivalent
OR, odds ratio
QoL, quality of life
STS, sodium thiosulphate
tPA, tissue plasminogen activator
Journal
Mayo Clinic proceedings. Innovations, quality & outcomes
ISSN: 2542-4548
Titre abrégé: Mayo Clin Proc Innov Qual Outcomes
Pays: Netherlands
ID NLM: 101728275
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
entrez:
30
1
2023
pubmed:
31
1
2023
medline:
31
1
2023
Statut:
epublish
Résumé
To describe the pain intensity among hospitalized patients with calciphylaxis, elucidate the factors associated with pain improvement, and examine the link between pain improvement and clinical outcomes. Patients were identified from the Partners Research Patient Data Registry and the Partners Calciphylaxis Registry and Biorepository (Clinicaltrials.gov ID: NCT03032835). Those with calciphylaxis requiring hospitalization for at least 14 consecutive days during the study period from May 2016 through December 2021 were included. Pain intensity was assessed using patient-reported pain scores on numerical rating scales from 0 to 10. Associations between pain improvement and clinical outcomes, including lesion improvement, amputation, and mortality, were examined using univariate and multivariate regression models. Our analysis included 111 patients (age, 58±14 years; men, 40%; on maintenance dialysis, 79%). No significant improvement of pain intensity was observed over the 14 days of hospitalization (mean difference, -0.71; Pain control remains a challenge among hospitalized patients with calciphylaxis. Surgical debridement and hyperbaric oxygen therapy may improve pain intensity. Pain improvement predicted a lower risk of future amputation.
Identifiants
pubmed: 36712824
doi: 10.1016/j.mayocpiqo.2022.12.006
pii: S2542-4548(23)00001-2
pmc: PMC9880339
doi:
Banques de données
ClinicalTrials.gov
['NCT03032835']
Types de publication
Journal Article
Langues
eng
Pagination
81-92Informations de copyright
© 2023 The Authors.
Références
Clin Nephrol. 2011 Jun;75(6):485-90
pubmed: 21612750
Nephrol Dial Transplant. 2013 May;28(5):1232-40
pubmed: 23291368
Med J Malaysia. 2019 Feb;74(1):25-29
pubmed: 30846658
J Am Soc Nephrol. 2016 Nov;27(11):3421-3429
pubmed: 27080977
J Pain Symptom Manage. 2006 Aug;32(2):186-90
pubmed: 16877187
BMC Nephrol. 2020 Sep 18;21(1):403
pubmed: 32948131
J Am Acad Dermatol. 2007 Apr;56(4):569-79
pubmed: 17141359
Nephrology (Carlton). 2018 Jul;23(7):669-675
pubmed: 28603903
J Dermatolog Treat. 2016 Nov;27(6):520-524
pubmed: 27051974
Dermatol Surg. 2009 Mar;35(3):554-5
pubmed: 19250296
Clin Nephrol. 2011 Jan;75(1):8-15
pubmed: 21176746
JAMA Dermatol. 2013 Jan;149(1):63-7
pubmed: 23324758
Curr Opin Nephrol Hypertens. 2021 Jul 1;30(4):424-429
pubmed: 34027904
Br J Dermatol. 2017 Dec;177(6):1510-1518
pubmed: 28580642
Kidney Int Rep. 2018 Oct 09;4(2):231-244
pubmed: 30775620
Curr Opin Nephrol Hypertens. 2019 Sep;28(5):448-454
pubmed: 31169527
Adv Chronic Kidney Dis. 2019 Nov;26(6):484-490
pubmed: 31831126
Mayo Clin Proc. 2016 Oct;91(10):1395-1402
pubmed: 27712638
Mayo Clin Proc. 2016 Oct;91(10):1384-1394
pubmed: 27712637
Dermatol Ther. 2020 Jul;33(4):e13587
pubmed: 32410269
J Pain Symptom Manage. 2022 May;63(5):711-720
pubmed: 34995683
J Am Acad Dermatol. 2021 Oct;85(4):1057-1064
pubmed: 33130181
Semin Dial. 2010 Jan-Feb;23(1):38-42
pubmed: 20331817
Clin Kidney J. 2021 Jul 06;15(1):136-144
pubmed: 35035944
Undersea Hyperb Med. 2020 First Quarter;47(1):111-123
pubmed: 32176952
PLoS One. 2019 Jun 13;14(6):e0218155
pubmed: 31194797